Clinical Scorecard: Comparative Analysis of Hemorrhagic Transformation Imaging Following Tenecteplase and Alteplase in Clinical Practice

At a Glance

Key Highlights

• No significant difference in symptomatic intracranial hemorrhage (sICH) incidence between tenecteplase and alteplase.
• Higher baseline NIHSS score and longer onset-to-needle time associated with increased intracranial hemorrhage.
• Remote hemorrhagic phenotypes were numerically more frequent in the tenecteplase group.
• Ordinal shift in hemorrhagic transformation severity did not differ significantly between treatment groups.
• Study findings are preliminary due to limited sample size.

Guideline-Based Recommendations

Diagnosis

• Clinically diagnosed acute ischemic stroke based on symptoms and neurological examination.

Management

• Intravenous thrombolysis with alteplase or tenecteplase within guideline-recommended time windows.

Monitoring & Follow-up

• Follow-up imaging within 24 hours after thrombolysis to assess hemorrhagic transformation.

Risks

• Hemorrhagic transformation remains a major complication of intravenous thrombolysis.

Patient & Prescribing Data

Patients aged ≥ 18 years with acute ischemic stroke.

Treatment with either alteplase (0.9 mg/kg) or tenecteplase (0.25 mg/kg) based on institutional protocols.

Clinical Best Practices

• Utilize the Heidelberg Bleeding Classification for assessing hemorrhagic transformation severity.
• Consider baseline NIHSS score and onset-to-needle time as predictors for intracranial hemorrhage.

Related Resources & Content